Cytori Therapeutics Inc (NASDAQ:CYTX) announced that it has entered into definitive agreements with certain holders (the “Consenting Holders”) of approximately 100% of its outstanding …
Cytori Therapeutics Inc (NASDAQ:CYTX) announced that it has received formal confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that Cytori’s request for an oral …
Maxim’s healthcare analyst Jason Kolbert reiterated coverage on the clinical-stage biopharmaceutical company Anavex Life Sciences Corp. (NASDAQ:AVXL) and cell therapy company Cytori Therapeutics Inc (NASDAQ:CYTX).
Cytori Therapeutics Inc (NASDAQ:CYTX) announced the finding of sustained benefit at two-year follow-up in the SCLERADEC-I trial of Cytori Cell Therapy (ECCS-50) in patients …
Cytori Therapeutics Inc (NASDAQ:CYTX) announced the signing of a non-exclusive, 3 year distribution agreement with Worthington Biochemical Corporation for Celase® GMP enzyme for research …
Cytori Therapeutics Inc (NASDAQ:CYTX) announced the publication of preclinical data demonstrating that Cytori Cell Therapy can promote burn wound healing via topical spray delivery, …
Cytori Therapeutics Inc (NASDAQ:CYTX) announced the publication of the results of a pilot clinical trial of Cytori Cell Therapy™ for the treatment of recalcitrant …
Cytori Therapeutics Inc (NASDAQ:CYTX) announced that the first patient has been enrolled and treated in the SCLERADEC-II trial, a late phase, follow-on European clinical …
Roth Capital’s healthcare analyst Joseph Pantginis weighed in today with a few insights on Cytori Therapeutics Inc (NASDAQ:CYTX), after the company announced mature data and publication in …
Cytori Therapeutics Inc (NASDAQ:CYTX) announced the publication today of the results from the 12 month clinical follow up of patients enrolled in the Scleradec-I …
